- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00226109
Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics (SPICA)
Effect of Spironolactone Treatment on Heart- and Skeletal Muscle in Chronic Alcoholics
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Our department has done research into skeletal muscle function in patients with liver cirrhosis. Post-hoc analyses of one of these studies suggested that treatment with spironolactone had a positive effect on muscle strength and endurance. This effect was probably caused by an increase in concentration of Na, K-pumps (sodium-potassium pumps) enabling the muscle cell perform better.
To verify this finding we have designed a double-blinded, placebo-controlled, randomized clinical trial with skeletal muscle strength, -endurance, Na, K-pump content, cardiac systolic, and diastolic function as primary endpoints. Spironolactone is tested against placebo in 40 participants included among our admitted and out-clinic patients. Muscle function-tests, muscle biopsy and trans-thoracic echocardiography is performed before and after 12 weeks of treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 9000
- Department of Medicine V (gastroenterology and hepatology)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Alcoholism, male gender
Exclusion Criteria:
- Spironolactone treatment
- Tense ascites
- Hepatic encephalopathy
- Dementia
- Cancer
- Severe psychiatric disease
- Untreated thyroid disease
- Maltreated diabetes
- Spironolactone contraindications
- Kidney failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
|
100 mg once daily.
Can be reduced to 50 mg a day still maintaining the doubled-blinded status
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Muscle strength
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Muscle endurance
Time Frame: At 0 and 12 weeks
|
At 0 and 12 weeks
|
Content of Na,K-pump in skeletal muscle
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Content of sodium and potassium in skeletal muscle
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Steptest result
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Diastolic heart function
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Systolic heart function
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Muscle mass
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
QTc interval
Time Frame: 0 and 12 weeks
|
0 and 12 weeks
|
Magnesium retention
Time Frame: 0, 6, and 12 weeks
|
0, 6, and 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hendrik Vilstrup, Proffessor, Univeristy of Aarhus
- Study Director: Peter Holland-Fischer, MD, University of Aarhus
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Heart Diseases
- Cardiovascular Diseases
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcohol-Induced Disorders
- Alcoholism
- Cardiomyopathies
- Cardiomyopathy, Alcoholic
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Spironolactone
Other Study ID Numbers
- AFDV01
- 01 (Miami VAHS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholism
-
Yale UniversityCompletedFamilial Alcoholism VulnerabilityUnited States
-
Yonsei UniversityTerminated
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
University of Southern DenmarkActive, not recruitingGeneral Practice | Alcohol Abuse Alcoholism | Screening and Brief InterventionDenmark
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedEffects of Family History of Alcoholism and Sex on Alcohol AnalgesiaUnited States
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcoholic Liver Disease | Alcoholism,United States
-
Khoo Teck Puat HospitalNot yet recruitingEmergencies | Alcohol Use Disorder | Alcoholism and Alcohol Abuse
-
National Institute on Drug Abuse (NIDA)The Peter G. Dodge Foundation (PGDF)Completed
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Yale University; University...CompletedAlcoholismUnited States
-
University of Sao PauloCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsEnrolling by invitation
Clinical Trials on spironolactone
-
Medical University of South CarolinaWithdrawn
-
Medical University of South CarolinaWithdrawnHidradenitis Suppurativa
-
Columbia UniversityCompletedHeart FailureUnited States
-
Asan Medical CenterCompletedHeart FailureKorea, Republic of
-
Yonsei UniversityWithdrawn
-
Instituto Nacional de Ciencias Medicas y Nutricion...TerminatedPatients With Fungic InfectionsMexico
-
Assistance Publique - Hôpitaux de ParisSociété de Dermatologie FrançaiseCompletedCutaneous Atrophy Due to CorticosteroidsFrance
-
State University of New York - Upstate Medical...WithdrawnEnd Stage Renal Disease | Congestive Heart FailureUnited States
-
Hebei Medical UniversityTerminatedHeart Failure, CongestiveChina
-
US Department of Veterans AffairsCompleted